

F. Joly^{1,2,3,4}, P. Pautier⁵, E. Kalbacher⁶, F. Gernier^{1,2}, R. Fauvet^{2, 3,15,16}, F., A. Floquet⁷, D. Berton-Rigaud⁸, O. Tredan⁹, P. Follana¹⁰, J. Alexandre¹¹, A. Zannetti¹², N. Dohollou¹³, S. Trager¹⁴, I. Licaj^{1,2}, J-M Grellard¹, B. Clarisse¹, D. Ahmed-Lecheheb^{1,2}, C. Rousset-Jablonski⁹, A. Gompel¹⁶

¹Clinical Research Department, Centre François Baclesse, Caen FR, ²INSERM, U1086, Caen, FR, ³University of Caen Normandy, UMR-S1077, Caen, FR, ⁴Department of Oncology, CHU de Caen, Caen, FR, ⁵Department of Oncology, Gustave Roussy, Villejuif, FR, ⁶Department of Oncology, CHU Jean Minjoz, Besançon, FR, ⁷Department of Oncology, Institut Bergonie, Bordeaux, FR, ⁸ Institut de Cancérologie de l'Ouest, Site René Gauducheau, Department of Oncology, Saint Herblain, FR, ⁹ Department of Oncology, Centre Léon Bérard, Lyon, FR, ¹⁰ Department of Oncology, Centre Antoine Lacassagne, Nice, FR ¹¹ Department of Oncology, Hôpital Cochin, Paris, FR, ¹² Department of Oncology, Centre Hospitalier de Cholet, Cholet, FR, ¹³ Department of Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, FR, ¹⁴ GHPSO Site de Sentes, Senlis, FR; ¹⁵ Department of Gynecology and Obstetrics, Caen University Hospital, Caen, FR; ¹⁶ INSERM UMRS 1007, Paris Descartes University, Paris, FR.

BACKGROUND

- Despite the poor prognosis of epithelial ovarian cancer (EOC), **more than 40% of patients survive five years or longer after diagnosis.**
- We have previously shown, in *Vivrovaire 1* that EOC and its treatments induce **more long term fatigue and a negative impact on Quality of Life (QoL)**, compared to healthy controls (*Joly et al, Ann Oncol 2019*).
- Among EOC survivors, a subgroup of patients participated to the VIVROVAIRE2 study that evaluated gynecological sequelae. The aim of the present research was to report the **main menopausal symptoms (MS)** of EOC survivors and **hormone replacement therapy (HRT)**.

METHODS

- Vivrovaire1**
322 EOC survivors free of relapse ≥3 years after 1st line treatment
- FACT-G
 - FACT-O
 - FACT Fatigue
 - HADS
- Vivrovaire 2**
166 patients of the 322 EOC survivors
- detailed gynecological consultation
 - questionnaire related to menopausal symptoms
 - a clinical examination
 - an osteodensitometry.
- Menopausal symptoms (MS) were defined as **hot flashes and/or night sweats** and were described according to **natural menopause (NM)** or **surgically induced menopause (SIM)**.
 - Contraindication of HRT: low grade serous & endometrioid adenocarcinomas.


RESULTS

- All the EOCS had surgery, 97% received platinum and taxane chemotherapy, median delay from treatment was 5 years and 36% had surgical induced menopause.
- Osteoporosis was observed among 14 % of patients (similar to the general population).
- 52%** (85) reported either **hot flashes** (47%) or **night sweats** (32%): **72% with surgically induced menopause (SIM)**, compared to 41% with natural menopause (NM) (p<0.001).
- MS were not associated with QoL or fatigue.
- At the time of the survey, **5%** (n=5 SIM & n=3 NM) EOC survivors received hormone replacement therapy (HRT).
- Among the 85 EOC survivors with MS, 6%** (n=3 SIM &n= 2 NM) received hormone replacement therapy (HRT), **76% without HRT contraindication**


Characteristic (n=166)	Value
Age: Mean [range] years	62 [20-83]
Age at surgery: Mean [range] years	56 [15- 79]
Time since end of treatment : Median [range] years	5 [3-24]
FIGO stages n(%)	
I / II	85 (52)
III/IV	78 (48)
unknown	3
Grades n(%)	
low	68 (41)
high	85 (51)
unknown	13 (8)
Histology n(%)	
serous	86(52)
endometrioid	30 (18)
clear cells	35 (21)
mucinous	8 (5)
undifferentiated	5(3)
other	2 (1)

Histological subtypes and indication of HRT	
No Contraindication of HRT	120 (75)
high grade serous	47(31)
endometrioid G2-3	22 (14)
clear-cell	35 (21)
mucinous	8 (5)
undifferentiated	8 (5)
CI of HRT	41 (25)
low grade serous	35 (21)
endometrioid G1	6 (4)

AETIOLOGY of MENOPAUSE



Hormone replacement therapy and menopausal symptoms



Main menopausal symptoms (MS) of EOC survivors

N (%)	surgically induced menopause n=59 (35.5)	natural menopause n=107 (65.5)	P value	Total n= 166
menopausal symptoms	42 (72)	44 (41)	p<0.001	85(52)
hot flashes	40 (70.2)	38 (35.5)	P<0.0001	78 (47)
night sweats	27 (47.4)	26 (24.3)	P<0.01	54 (32)

N (%)	Menopausal symptoms 85 (52)	No menopausal symptoms 79 (48)
Age in years: Mean [range]	58 [20-80]	66 [39-83]
Age at surgery: Mean [range] years	52 [15-74]	60 [30-79]
No CI of HRT	63 (76%)	56 (74%)

Take home message

Half of the EOC survivors reported menopausal symptoms, particularly among patients with surgically induced menopause (72%). Only 6% of EOC survivors with menopausal symptoms benefited hormone replacement therapy while ¾ had no contraindication.